Six years ago, my doctor told me I had prostate cancer, and the news literally brought me to my knees. To…
Continue Reading
On August 13, 2015, Medicare approved coverage of the Prolaris® test for men diagnosed with low-risk and very low-risk prostate cancer.…
Continue Reading
Myriad has led the industry in genetic testing for hereditary breast and ovarian cancer since the launch of BRACAnalysis® in 1996.…
Continue Reading
All of us at Myriad – from the executives and researchers, to the sales and customer service representatives – work hard…
Continue Reading
Data recently presented by Myriad Genetics’ prostate cancer prognostic test Prolaris is getting healthcare professionals and patients interested in learning more…
Continue Reading SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal…
Continue Reading This past week Myriad Genetic Laboratories had the opportunity to present 2 posters at the Society for Urologic Oncologists that was…
Continue Reading SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA…
Continue Reading The Great Prostate Cancer Challenge (GPCC) is the premier men’s health race and event series in America. It is an exciting…
Continue Reading This BRCA2 positive patient has had a mastectomy and prostatectomy. Yes, you read that correctly. Meet Robert, a male HBOC carrier…
Continue Reading